Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10282	Fosifidancitinib
BP10282	Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.
BP10041	Fostamatinib Disodium
BP10041	Fostamatinib Disodium is an orally available Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities.
BP10219	Fruquintinib
BP10219	Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.
BP10810	FTI-277 hydrochloride
BP10810	FTI 277 hydrochloride is an effective and specific farnesyltransferase (FTase) inhibitor (IC50: 500 pM); this selectivity is about 100-fold than the closely related GGTase I.
BP10343	Fulvestrant
BP10343	Fulvestrant is a potent Estrogen Receptor antagonist (IC50: 9.4 nM).
BP10916	Furanodiene
BP10916	Furanodiene has anti-inflammatory and antioxidant activities, it is active against gram-positive bacteria and Candida albicans.
BP10546	Futibatinib
BP10546	TAS-120 is a novel, potent and highly selective FGFR inhibitor, used for antitumor treatment.
BP10513	FX1
BP10513	FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM).
BP10403	G-744
BP10403	G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthritis.
BP10566	G-749
BP10566	G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
BP10596	Gallic acid
BP10596	Gallic acid is found in almost all plants. Plants known for their high gallic acid content include gallnuts,grapes,tea,hops and oak bark.
BP10270	Gandotinib
BP10270	LY2784544(Gandotinib) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM). The selectivity is higher 8- and 20-fold than JAK1 and JAK3.
BP10010	Ganoderenic acid D
BP10010	Ganoderenic acid D is a natural product isolated from the effective compounds of Ganoderma lucidum extract (GLE). Ganoderenic acid D induces cell cycle arrest and apoptosis and inhibits the proliferation of cancer cells.
BP10112	Ganoderic acid D
BP10112	1. Ganoderic acid D is one of the major components in Ganoderma triterpenes. 2. Ganoderic acid D treatment for 48h inhibits the proliferation of HeLa human cervical carcinoma cells with an IC(5) value of 17.3 +/- .3 microM.
BP10824	GDC-0214
BP10824	GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).
BP10185	GDC-0623
BP10185	GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.
BP10159	GDC-0834
BP10159	GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, respectively. GDC-0834 is a potent and selective BTK inhib
BP10834	Gefitinib
BP10834	Gefitinib is an EGFR tyrosine kinase inhibitor and can inhibit Tyr1173, Tyr992, Tyr1173 and Tyr992 (IC50s: 37/37/26/57 nM).
BP10994	Gemcitabine elaidate
BP10994	Gemcitabine elaidate, is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.
BP10248	Gemcitabine hydrochloride
BP10248	Gemcitabine is a DNA synthesis inhibitor (IC50s: 12, 18, 40, 92.7, 89.3 in Capan2, BxPC-3, Mia Paca-2, PANC-1, and PL-45 cells, respectively).